KPV Legal Status, FDA 503A Category, and Compounding Access

The short version

Here is the KPV legal status in plain terms. KPV is not an FDA-approved medicine for anything. In the United States, a pharmacy can compound a drug from a raw ingredient only if that ingredient clears a specific gate — it has an official quality monograph, it is part of an already-approved drug, or it is on FDA's special "bulks list." KPV is not on that list. It has, however, been put on the schedule for an FDA advisory committee to discuss in July 2026 as a possible future addition. That is a scheduled conversation, not a decision, and nothing about KPV's status has changed yet.

The current FDA position on KPV

KPV legal status starts from a fixed, citable fact: KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH) — is a research peptide and is not an FDA-approved drug for any indication ^[16]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list ^[16]. Substances not yet on that list are evaluated by FDA through a public nomination process informed by the Pharmacy Compounding Advisory Committee (PCAC) ^[16].

KPV is one of the bulk drug substances FDA has scheduled for PCAC evaluation ^[18]. Being under evaluation is not the same as being on the bulks list, and it is not the same as being approved for compounding. FDA's published page for this meeting lists KPV as a substance "being considered for inclusion on the 503A Bulks List" — language that, by its own terms, describes a candidate under review, not a listed or approved ingredient ^[18]. The present-tense status of KPV is therefore precise and limited: a research peptide, not FDA-approved, scheduled for PCAC evaluation.

Access is under active FDA review and may expand in 2026

The forward-looking fact is genuine, and it is stated with care. KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026 as a bulk drug substance "being considered for inclusion on the 503A Bulks List" ^[18]. FDA's calendar lists it in both its free base and acetate forms, alongside BPC-157, TB-500, and MOTs-C as other substances scheduled for the same discussion ^[18]. That an ingredient reaches this agenda means FDA considers it worth a structured public evaluation — which is real momentum in the regulatory process, and the reason access could change.

But the agenda is the beginning of an evaluation, not its conclusion. A PCAC discussion is advisory; it is not a final FDA decision, not a reclassification, and not a change in current status ^[18]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC, and being discussed by PCAC is a step in evaluation, not a listing decision ^[16]. The honest framing is momentum without a verdict: KPV's access question is genuinely live and on FDA's calendar, while its present status remains exactly what it is today.

What being scheduled for evaluation does not mean

Because this is the point readers most often get wrong, it is worth stating directly what the July 2026 agenda does not establish. It does not mean KPV has been added to the 503A bulks list. It does not mean KPV has been reclassified, approved, or cleared for compounding. It does not carry a guaranteed outcome or a fixed date for any decision, and the outcome of the meeting is unknown ^[18]. Separately, some commercial and clinic sources have circulated claims of a sweeping early-2026 reclassification of bulk-substance peptides, or specific dated "removals" of individual peptides; those reports could not be confirmed from an authoritative FDA source and are not treated as fact here. This page reports only what FDA's own pages establish, in the present tense.

The 503A and 503B framework, in brief

Drug compounding in the U.S. runs through two sections of the law. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient ^[16]. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection ^[16]. In either setting, a compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list; otherwise the substance must be nominated and evaluated by FDA ^[16]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding — and KPV is neither an approved drug nor, at present, a listed bulk substance ^[16][18].

How legally compounded peptide access works

In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[17]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[17]. Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded or remove the need for a legitimate prescriber-patient relationship and a valid prescription ^[17].

The ingredient-eligibility caveat is decisive and applies to KPV today: a compounder may use a requested active ingredient only if that ingredient is eligible under the 503A/503B bulk-substance rules ^[17]. An ingredient that FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[17]. This page names no specific pharmacy, clinic, telehealth provider, or vendor, gives no dosing or administration instructions, and describes no way to obtain any substance outside the lawful framework. It is general information about the regulatory landscape — not medical or legal advice, and not an offer to sell or supply any substance.